Castle Biosciences (CSTL) Current Deferred Revenue (2020 - 2021)
Castle Biosciences' (CSTL) quarterly Current Deferred Revenue came in at $3.0 million in Q3 2021, down 64.08% year-on-year from $8.4 million in Q3 2020, and down 51.45% quarter-over-quarter from $6.2 million in Q2 2021.
Castle Biosciences (CSTL) Current Deferred Revenue (2020 - 2021) Analysis & Trends
Castle Biosciences has disclosed Current Deferred Revenue across 2 years of filings, most recently posting $3.0 million for Q3 2021.
- Current Deferred Revenue for Q3 2021 came in at $3.0 million, down 64.08% year-over-year; the trailing twelve-month figure through Sep 2021 was $3.0 million (down 64.08% YoY), and the FY2020 annual result was $6.6 million, changed N/A from the prior year.
- Current Deferred Revenue came in at $3.0 million for Q3 2021 at Castle Biosciences, down from $6.2 million in the prior quarter.
- In the past five years, Current Deferred Revenue ranged from a high of $8.4 million in Q2 2020 to a low of $3.0 million in Q3 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Waters | 30,529.42 Bn | 30,528.96 Bn | 1.11 Bn |
| 2 | Thermo Fisher Scientific | 183.75 Bn | 180.50 Bn | 7.74 Bn |
| 3 | Danaher | 133.13 Bn | 127.43 Bn | 3.59 Bn |
| 4 | Idexx Laboratories | 46.14 Bn | 45.94 Bn | 722.74 Mn |
| 5 | Agilent Technologies | 38.20 Bn | 36.39 Bn | 990.00 Mn |
| 6 | Natera | 31.50 Bn | 30.40 Bn | 696.04 Mn |
| 7 | Iqvia Holdings | 31.34 Bn | 29.36 Bn | 1.36 Bn |
| 8 | Illumina | 24.51 Bn | 23.36 Bn | 721.00 Mn |
| 9 | Mettler Toledo International | 23.53 Bn | 23.47 Bn | 555.82 Mn |
| 10 | Castle Biosciences | 629.76 Mn | 368.04 Mn | 63.15 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2021 | 3.00 Mn |
| Jun 30, 2021 | 6.18 Mn |
| Mar 31, 2021 | 8.18 Mn |
| Dec 31, 2020 | 6.62 Mn |
| Sep 30, 2020 | 8.35 Mn |
| Jun 30, 2020 | 8.35 Mn |